Dynamics of Tumor Hypoxia in Response to Patupilone and Ionizing Radiation

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Orlowski, Katrin ^a,b   Rohrer Bley, Carla ^b   Zimmermann, Martina ^a   Vuong, Van ^a   Hug, Daniel ^a   Soltermann, Alex ^a   Broggini Tenzer, Angela ^a   Pruschy, Martin ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPOTHILONE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DEGRADATION; DRUG CYTOTOXICITY; DRUG RESPONSE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; OXYGEN CONCENTRATION; OXYGEN DEPENDENT DEGRADATION; REPORTER GENE; TISSUE OXYGENATION; TUMOR HYPOXIA; TUMOR XENOGRAFT;

ANIMALS; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; COBALT; COMBINED MODALITY THERAPY; EPOTHILONES; GENES, REPORTER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; MICE; MICE, NUDE; NEOPLASMS; NITROIMIDAZOLES; OXYGEN; PARTIAL PRESSURE; PROTEIN STRUCTURE, TERTIARY; RADIATION, IONIZING; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870942768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051476     Document Type: Article

References (52)

1. Chapman JD, Dugle DL, Reuvers AP, Meeker BE, Borsa J, (1974) Letter: Studies on the radiosensitizing effect of oxygen in Chinese hamster cells. Int J Radiat Biol Relat Stud Phys Chem Med 26: 383-389.
2. Wachsberger P, Burd R, Dicker AP, (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9: 1957-1971.
3. Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S, et al. (2006) Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res 12: 3518-3524.
4. Oehler-Janne C, Jochum W, Riesterer O, Broggini-Tenzer A, Caravatti G, et al. (2007) Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models. Mol Cancer Ther 6: 2496-2504.
5. Hofstetter B, Vuong V, Broggini-Tenzer A, Bodis S, Ciernik IF, et al. (2005) Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 11: 1588-1596.
6. Bley CR, Jochum W, Orlowski K, Furmanova P, Vuong V, et al. (2009) Role of the microenvironment for radiosensitization by patupilone. Clin Cancer Res 15: 1335-1342.
7. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, et al. (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631.
8. Sparano JA (2000) Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 1: 32-40; discussion 41-32.
9. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, et al. (2004) The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science 305: 866-869.
10. Altmann KH, Pfeiffer B, Arseniyadis S, Pratt BA, Nicolaou KC, (2007) The chemistry and biology of epothilones-the wheel keeps turning. ChemMedChem 2: 396-423.
11. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, et al. (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55: 2325-2333.
12. Altmann KH, Wartmann M, O'Reilly T, (2000) Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470: M79-91.
13. Gradishar W, (2009) Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des Devel Ther 3: 163-171.
14. Fogh S, Machtay M, Werner-Wasik M, Curran WJ Jr, Bonanni R, et al. (2010) Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 77: 1009-1016.
15. Stupp R, Tosoni A, Bromberg JE, Hau P, Campone M, et al. (2011) Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol 22: 2144-2149.
16. Dumontet C, Jordan MA, (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9: 790-803.
17. Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, et al. (2011) Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer 105: 1646-1653.
18. Kamath K, Okouneva T, Larson G, Panda D, Wilson L, et al. (2006) 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther 5: 2225-2233.
19. Chen JG, Yang CP, Cammer M, Horwitz SB, (2003) Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 63: 7891-7899.
20. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, et al. (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825.
21. Ogasawara M, Matsubara T, Suzuki H, (2001) Screening of natural compounds for inhibitory activity on colon cancer cell migration. Biol Pharm Bull 24: 720-723.
22. Westerlund A, Hujanen E, Hoyhtya M, Puistola U, Turpeenniemi-Hujanen T, (1997) Ovarian cancer cell invasion is inhibited by paclitaxel. Clin Exp Metastasis 15: 318-328.
23. Pawlik TM, Keyomarsi K, (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942.
24. Milas L, Saito Y, Hunter N, Milross CG, Mason KA, (1996) Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. Radiother Oncol 40: 163-170.
25. Wenger RH, Stiehl DP, Camenisch G, (2005) Integration of oxygen signaling at the consensus HRE. Sci STKE 2005: re12.
26. Wenger RH, (2002) Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 16: 1151-1162.
27. Lehmann S, Stiehl DP, Honer M, Dominietto M, Keist R, et al. (2009) Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci U S A 106: 14004-14009.
28. Harada H, Kizaka-Kondoh S, Itasaka S, Shibuya K, Morinibu A, et al. (2007) The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 360: 791-796.
29. Kim HA, Kim K, Kim SW, Lee M, (2007) Transcriptional and post-translational regulatory system for hypoxia specific gene expression using the erythropoietin enhancer and the oxygen-dependent degradation domain. J Control Release 121: 218-224.
30. Escuin D, Kline ER, Giannakakou P, (2005) Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65: 9021-9028.
31. Lu Y, Liang K, Li X, Fan Z, (2007) Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer 6: 63.
32. Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, et al. (2007) Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26: 7508-7516.
33. Carbonaro M, O'Brate A, Giannakakou P, (2011) Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. J Cell Biol 192: 83-99.
34. Moeller BJ, Cao Y, Li CY, Dewhirst MW, (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441.
35. Waldman T, Kinzler KW, Vogelstein B, (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-5190.
36. Chao SK, Lin J, Brouwer-Visser J, Smith AB 3rd, Horwitz SB, et al (2010) Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent. Proc Natl Acad Sci U S A 108: 391-396.
37. Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, et al. (2006) Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 103: 105-110.
38. Rohrer Bley C, Orlowski K, Furmanova P, McSheehy PM, Pruschy M, (2011) Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells. Lung Cancer 73: 294-301.
39. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, et al. (2007) Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26: 63-74.
40. Stiehl DP, Wirthner R, Koditz J, Spielmann P, Camenisch G, et al. (2006) Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J Biol Chem 281: 23482-23491.
41. Oehler C, von Bueren AO, Furmanova P, Broggini-Tenzer A, Orlowski K, et al. (2011) The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells. Neuro Oncol 13: 1000-1010.
42. Nordsmark M, Overgaard J, (2004) Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 43: 396-403.
43. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW, (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285-289.
44. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, et al. (1988) Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14: 831-838.
45. Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R, (1999) Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 53: 99-104.
46. Le QT, Chen E, Salim A, Cao H, Kong CS, et al. (2006) An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 12: 1507-1514.
47. Yaromina A, Kroeber T, Meinzer A, Boeke S, Thames H, et al. (2011) Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 80: 1205-1213.
48. Goldman SJ, Chen E, Taylor R, Zhang S, Petrosky W, et al. (2011) Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice. PLoS One 6: e18269.
49. Dubois L, Landuyt W, Haustermans K, Dupont P, Bormans G, et al. (2004) Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 91: 1947-1954.
50. Hlushchuk R, Riesterer O, Baum O, Wood J, Gruber G, et al. (2008) Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol 173: 1173-1185.
51. Ferretti S, Allegrini PR, O'Reilly T, Schnell C, Stumm M, et al. (2005) Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 11: 7773-7784.
52. Viola RJ, Provenzale JM, Li F, Li CY, Yuan H, et al. (2008) In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy. AJR Am J Roentgenol 191: 1779-1784.